Lasa Supergenerics Limited

NSEI:LASA Stock Report

Market Cap: ₹1.3b

Lasa Supergenerics Past Earnings Performance

Past criteria checks 0/6

Lasa Supergenerics's earnings have been declining at an average annual rate of -50.7%, while the Pharmaceuticals industry saw earnings growing at 13.6% annually. Revenues have been declining at an average rate of 11.6% per year.

Key information

-50.7%

Earnings growth rate

-44.6%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate-11.6%
Return on equity-25.0%
Net Margin-19.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Little Excitement Around Lasa Supergenerics Limited's (NSE:LASA) Revenues

Dec 10
Little Excitement Around Lasa Supergenerics Limited's (NSE:LASA) Revenues

There's No Escaping Lasa Supergenerics Limited's (NSE:LASA) Muted Revenues

Aug 08
There's No Escaping Lasa Supergenerics Limited's (NSE:LASA) Muted Revenues

We Think Lasa Supergenerics (NSE:LASA) Has A Fair Chunk Of Debt

Jun 05
We Think Lasa Supergenerics (NSE:LASA) Has A Fair Chunk Of Debt

Little Excitement Around Lasa Supergenerics Limited's (NSE:LASA) Revenues As Shares Take 26% Pounding

Mar 13
Little Excitement Around Lasa Supergenerics Limited's (NSE:LASA) Revenues As Shares Take 26% Pounding

Improved Revenues Required Before Lasa Supergenerics Limited (NSE:LASA) Stock's 25% Jump Looks Justified

Dec 28
Improved Revenues Required Before Lasa Supergenerics Limited (NSE:LASA) Stock's 25% Jump Looks Justified

We Think Lasa Supergenerics (NSE:LASA) Has A Fair Chunk Of Debt

Jul 05
We Think Lasa Supergenerics (NSE:LASA) Has A Fair Chunk Of Debt

Lasa Supergenerics (NSE:LASA) Is Carrying A Fair Bit Of Debt

Mar 28
Lasa Supergenerics (NSE:LASA) Is Carrying A Fair Bit Of Debt

Lasa Supergenerics' (NSE:LASA) Dividend Will Be ₹0.25

Sep 02
Lasa Supergenerics' (NSE:LASA) Dividend Will Be ₹0.25

Would Lasa Supergenerics (NSE:LASA) Be Better Off With Less Debt?

Aug 13
Would Lasa Supergenerics (NSE:LASA) Be Better Off With Less Debt?

A Look At The Fair Value Of Lasa Supergenerics Limited (NSE:LASA)

Jun 21
A Look At The Fair Value Of Lasa Supergenerics Limited (NSE:LASA)

Is Lasa Supergenerics (NSE:LASA) Using Too Much Debt?

Dec 06
Is Lasa Supergenerics (NSE:LASA) Using Too Much Debt?

Revenue & Expenses Breakdown

How Lasa Supergenerics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NSEI:LASA Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,198-227660
30 Jun 241,046-195630
31 Mar 241,044-217660
31 Dec 231,168-214690
30 Sep 231,219-249500
30 Jun 231,312-315590
31 Mar 231,304-386800
31 Dec 221,455-1131010
30 Sep 221,295-111880
30 Jun 221,299-183920
31 Mar 221,371-53740
31 Dec 211,250-1391350
30 Sep 211,633-261580
30 Jun 211,8381821490
31 Mar 212,0242281450
31 Dec 202,1182161480
30 Sep 201,9721761400
30 Jun 201,8291011340
31 Mar 201,673361420
31 Dec 191,607-81390
30 Sep 191,753-861340
30 Jun 191,756-1011200
31 Mar 191,696-1201250
31 Dec 181,869-1671200
30 Sep 181,940-831160
30 Jun 182,175551150
31 Mar 182,4351231100
30 Jun 172,184-101020
31 Mar 172,18224980

Quality Earnings: LASA is currently unprofitable.

Growing Profit Margin: LASA is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: LASA is unprofitable, and losses have increased over the past 5 years at a rate of 50.7% per year.

Accelerating Growth: Unable to compare LASA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LASA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20.6%).

Return on Equity

High ROE: LASA has a negative Return on Equity (-25.04%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 17:20
End of Day Share Price 2025/01/23 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lasa Supergenerics Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution